AIM news

AIM ImmunoTech Inc. agreed to exchange promissory notes for common stock, reducing the outstanding loan balance. This exchange is structured to comply with Rule 144, marking a potential settlement of a significant debt.

AIM ImmunoTech reported Q2 financial results and completed dosing in its phase 2 pancreatic cancer trial, positioning the company for potential phase 3 development and key clinical data in late 2027.

AIM ImmunoTech has submitted a proposal to Sterling Pharma Solutions for the cGMP manufacture of PolyI and Poly C12U drug substance batches. This submission outlines a detailed project plan for the scale-up and manufacturing of polynucleotides in aqueous frozen solution at Sterling's Dudley site.

AIM ImmunoTech Inc. amended its bylaws effective June 9, 2026, modifying Section 1.9 of Article I to clarify voting procedures, proxy rules, and the voting standard for director elections and stockholder proposals. The amendment standardizes voting requirements to a plurality for director elections …

AIM ImmunoTech released a virtual investor video discussing Ampligen's potential application in treating Bundibugyo Ebola virus disease, highlighting preclinical research showing 100% protective survival in mouse models. The company emphasizes the unmet medical need for targeted therapies against th…

AIM ImmunoTech Inc. filed an exhibit detailing the terms of Class I Common Stock Purchase Warrants, which are unregistered securities exercisable after stockholder approval. The warrants include standard anti-dilution provisions and define exercise mechanics tied to various trading market pricing me…